Clinical outcomes in relapsed oropharyngeal cancer after definitive (chemo) radiotherapy

Oral Dis. 2023 Mar;29(2):595-603. doi: 10.1111/odi.13985. Epub 2021 Aug 27.

Abstract

Objectives: To report clinical outcomes of relapsed oropharyngeal squamous cell carcinoma (OPSCC) after definitive intensity-modulated (chemo)radiotherapy [(C)RT].

Materials and methods: Data for all relapsed patients treated for OPSCC with definitive (C)RT between 2010 and 2016 were collected. Primary end-point was post-failure survival (PFS).

Results: Overall, 273 OPSCC patients completed definitive (C)RT. Of these, 42 cases (n = 26 human papilloma virus (HPV)-negative; n = 16 HPV-positive) had relapsed (n = 23 persistent disease; n = 19 recurrent disease) and were included in the final analysis. Two-year PFS for the entire population was 30.6%; 20.5% for HPV-negative and 43.8% for HPV-positive patients. Salvage curative surgery was associated with a significantly higher 2 years PFS rate (56.2%) compared with palliative treatment (22.9%) and best supportive care (0%) (p < 0.001). A positive trend in 2 years PFS was recorded in the early complete response cases (49.5%) versus patients who did not achieve a complete response within 3 months of the end of (C)RT (23.0%) (p = 0.11).

Conclusion: A higher PFS rate is achieved when relapsed OPSCC cases are treated with salvage curative intent. HPV-positive disease and early complete response within 3 months from the end of (C)RT may be related to better PFS.

Keywords: chemoradiotherapy; failure; oropharyngeal cancer; recurrence; survival.

MeSH terms

  • Chronic Disease
  • Head and Neck Neoplasms* / complications
  • Human Papillomavirus Viruses
  • Humans
  • Mouth Neoplasms* / complications
  • Oropharyngeal Neoplasms* / drug therapy
  • Oropharyngeal Neoplasms* / radiotherapy
  • Papillomavirus Infections* / complications
  • Prognosis
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck